Harvest Portfolios Group Inc. Raises Position in Bristol Myers Squibb Company $BMY

Harvest Portfolios Group Inc. boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 17.2% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 1,327,460 shares of the biopharmaceutical company’s stock after buying an additional 195,091 shares during the period. Bristol Myers Squibb makes up approximately 1.1% of Harvest Portfolios Group Inc.’s investment portfolio, making the stock its 28th biggest position. Harvest Portfolios Group Inc.’s holdings in Bristol Myers Squibb were worth $59,868,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of BMY. Vanguard Group Inc. increased its position in shares of Bristol Myers Squibb by 0.5% in the third quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock worth $8,838,879,000 after purchasing an additional 1,058,803 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after buying an additional 10,195,775 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Bristol Myers Squibb by 1.6% in the 2nd quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company’s stock worth $2,132,976,000 after buying an additional 723,459 shares during the last quarter. Norges Bank purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $1,554,154,000. Finally, Ameriprise Financial Inc. lifted its holdings in shares of Bristol Myers Squibb by 1.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock worth $1,508,099,000 after acquiring an additional 432,158 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 1.9%

NYSE:BMY opened at $62.23 on Friday. The firm has a market capitalization of $126.74 billion, a P/E ratio of 18.04, a P/E/G ratio of 0.17 and a beta of 0.29. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The company has a fifty day moving average of $56.98 and a 200 day moving average of $50.52. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.Bristol Myers Squibb’s revenue was up 1.3% on a year-over-year basis. During the same period last year, the business earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. The ex-dividend date of this dividend was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is currently 73.04%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Leerink Partners increased their price objective on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Citigroup boosted their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Guggenheim reiterated a “buy” rating and set a $72.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Finally, Morgan Stanley restated an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $60.71.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase III interim topline results reported for izalontamab brengitecan (Iza‑bren) in previously treated unresectable locally advanced/metastatic triple‑negative breast cancer — the readout validates an ADC Bristol Myers licensed and could materially boost future revenue potential (deal carries >$8B long‑term economics that BMS has highlighted), which is likely the main driver lifting sentiment today. Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer
• Neutral Sentiment: Coverage pieces note BMY has lagged the Nasdaq over the last year, but Wall Street remains moderately optimistic — this frames today’s rally as driven more by idiosyncratic clinical news than by broad market leadership. Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?
• Neutral Sentiment: Sector updates and analyst writeups (momentum/value profiles) are highlighting BMY as a top‑ranked momentum/value/dividend candidate for different investor styles — these stories can attract additional retail and income‑oriented flows but are not major catalysts by themselves. Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
• Neutral Sentiment: General pharma‑sector coverage and updates mention BMY among large‑cap players with deep late‑stage pipelines — supportive context but not a standalone catalyst. Bristol Myers Squibb (NYSE:BMY) Update Pharma Sector Developments
• Negative Sentiment: RBC Capital initiated coverage with a Sector Perform rating and a $60 price target (implying slight downside versus recent levels); that cautious initiation caps upside for some investors and may limit the size of gains if broader sentiment cools. RBC Capital Initiates Bristol Myers (BMY) with $60 Target

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.